PDMS and PFO is effective as tamponade

Article

A study published in Clinical Ophthalmology has proved the efficacy of using polydimethyloxane (PDMS) and perfluoro-n-octane (PFO) as tamponade in patients with retinal detachment complicated by proliferative vitreoretinopathy (PVR).

A study published in Clinical Ophthalmology has proved the efficacy of using polydimethyloxane (PDMS) and perfluoro-n-octane (PFO) as tamponade in patients with retinal detachment complicated by proliferative vitreoretinopathy (PVR).

An investigation led by Dr Stefano Zenoni, Bergamno Hospital, Bergamo, Italy, aimed to evaluate ocular tolerance and efficacy of short-term tamponade with double-filling of PDMS and perfluoro-n-octane (PFO) in 30 patients. Double filling with 30% PFO and 70% PDMS was performed for a mean period of 23 days. Follow-up visits were scheduled for 1 week, 1 month and 3 months postoperatively. The main outcome measures included visual acuity, intraocular pressure (IOP), PVR reprofileration and electrophysiological parameters.

Of the 30 patients, 14 experienced improved postoperative visual acuity, 12 patients maintained preoperative visual acuity and 4 patients had a decrease in visual acuity. The average postoperative IOP was 19.7 mmHg. Nine patients experienced an increase in IOP, which was later treated with topical drops or systematic carbonic anhydrase.

Additionally, the researchers found a statistically significant difference in the data obtained with the electroretinogram (ERG) between week 4 and 8 of the follow-up period. There were no electroretinographic traces of retinal toxicity and there was a low occurrence of PVR reproliferation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.